{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:28:06Z","timestamp":1743341286919},"reference-count":200,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"National Health and Medical Research Council of Australia","award":["1138585"],"award-info":[{"award-number":["1138585"]}]},{"name":"The Centre for Eye Research Australia"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.2217\/pgs-2017-0183","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T09:28:35Z","timestamp":1522056515000},"page":"435-461","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Changing Vision: A Review of Pharmacogenetic Studies for Treatment Response in Age-Related Macular Degeneration Patients"],"prefix":"10.1080","volume":"19","author":[{"given":"Janan","family":"Arslan","sequence":"first","affiliation":[{"name":"Department of Surgery (Ophthalmology), Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye & Ear Hospital, East Melbourne, Victoria, 3002, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul N","family":"Baird","sequence":"additional","affiliation":[{"name":"Department of Surgery (Ophthalmology), Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye & Ear Hospital, East Melbourne, Victoria, 3002, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00021.2004"},{"key":"e_1_3_3_3_1","volume-title":"Methods in Pharmacology and Toxicology 6","author":"Cohen N","year":"2008","unstructured":"Cohen N . Pharmacogenomics and personalized medicine . In : Methods in Pharmacology and Toxicology 6 . KangYJ ( Ed. ). Humana Press , Totowa, NJ, USA ( 2008 )."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01498.x"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.86"},{"key":"e_1_3_3_7_1","unstructured":"US FDA . Table of pharmacogenomic biomarkers in drug labeling . www.fda.gov\/Drugs\/ScienceResearch\/ucm572698.htm ."},{"key":"e_1_3_3_8_1","unstructured":"US FDA . Safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and\/or adenoidectomy . www.fda.gov\/downloads\/drugs\/drugsafety\/ucm339116.pdf ."},{"key":"e_1_3_3_9_1","unstructured":"US FDA . Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling ( 2013 ). www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM337169.pdf ."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591577106400614"},{"key":"e_1_3_3_11_1","unstructured":"WHO . Blindness: vision 2020 \u2013 the global initiative for the elimination of avoidable blindness . www.who.int\/mediacentre\/factsheets\/fs213\/en\/ ."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003471"},{"key":"e_1_3_3_13_1","unstructured":"Vision 2020 Australia . Clear focus: the economic impact of vision loss in Australia in 2009. A report prepared for vision 2020 Australia by Access Economics Pty Limited ( 2010 ). http:\/\/www.vision2020australia.org.au\/uploads\/resource\/85\/Access_Economics_Clear_Focus_Full_Report.pdf ."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afv126"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12405"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.10.1.81"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-72802012000300011"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-090413-025610"},{"key":"e_1_3_3_20_1","volume-title":"Vision Problems Among Older Australians","author":"Australian Institute of Health and Welfare","year":"2005","unstructured":"Australian Institute of Health and Welfare . Vision Problems Among Older Australians . Australian Institute of Health and Welfare , Sydney, Australia ( 2005 )."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm212"},{"key":"e_1_3_3_22_1","unstructured":"The Department of Health \u2013 Australian Government . Section two: the epidemiology and impact of blindness and vision loss in Australia . www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/D1A5409787D800F2CA257C73007F12F3\/$File\/2.pdf ."},{"key":"e_1_3_3_23_1","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"8","author":"Solomon SD","year":"2014","unstructured":"Solomon SD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti-vascular endothelial growth factor for neovascular age-related macular degeneration . Cochrane Database Syst. Rev.8 , CD005139 ( 2014 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.032"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00030-4"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61759-6"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-22107-1"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030005"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.07.012"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.06.018"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.023"},{"key":"e_1_3_3_32_1","first-page":"335","article-title":"The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973\u20131975","volume":"24","author":"Leibowitz HM","year":"1980","unstructured":"Leibowitz HM , KruegerDE , MaunderLRet al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973\u20131975 . Surv. Ophthalmol.24 ( Suppl. ), 335 \u2013 610 ( 1980 ).","journal-title":"Surv. Ophthalmol."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728220902942322"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.150829"},{"issue":"3","key":"e_1_3_3_35_1","first-page":"103","article-title":"Dry age-related macular degeneration: a currently unmet clinical need","volume":"1","author":"Girmens JF","year":"2012","unstructured":"Girmens JF , SahelJA , MarazovaK . Dry age-related macular degeneration: a currently unmet clinical need . Intractable Rare Dis. Res.1 ( 3 ), 103 \u2013 114 ( 2012 ).","journal-title":"Intractable Rare Dis. Res."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10998.1"},{"key":"e_1_3_3_37_1","unstructured":"Roche . Media release . www.roche.com\/media\/store\/releases\/med-cor-2017-09-08b.htm ."},{"key":"e_1_3_3_38_1","unstructured":"Roche . Statement on chroma study . www.roche.com\/media\/store\/statements.htm ."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-29"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-9233.173134"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2015.448"},{"key":"e_1_3_3_42_1","unstructured":"Deloitte Access Economics ; MitchellP . Eyes on the future. A clear outlook on age-related macular degeneration . Deloitte Access Economics ( 2011 ). www.mdfoundation.com.au\/sites\/default\/files\/Deloitte_Eyes_on_the_Future_Report_web_1_0.pdf ."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S67536"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.11.027"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300654"},{"issue":"1","key":"e_1_3_3_46_1","first-page":"79","article-title":"Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents \u2013 on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)","volume":"114","author":"Golik P","year":"2012","unstructured":"Golik P , To\u0144skaK . Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents \u2013 on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor) . Klin. Oczna114 ( 1 ), 79 \u2013 83 ( 2012 ).","journal-title":"Klin. Oczna"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno\/v01p0395"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070544"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.658368"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.36474"},{"key":"e_1_3_3_52_1","first-page":"CD011230","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","volume":"9","author":"Moja L","year":"2014","unstructured":"Moja L , LucenteforteE , KwagKHet al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration . Cochrane Database Syst. Rev.9 , CD011230 ( 2014 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_53_1","first-page":"514","article-title":"ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration","volume":"23","author":"Nakai S","year":"2017","unstructured":"Nakai S , HondaS , MatsumiyaW , MikiA , NakamuraM . ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration . Molecular Vision23 , 514 \u2013 519 ( 2017 ).","journal-title":"Molecular Vision"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.007"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(00)00158-2"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10365"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1329"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm3010040"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357528"},{"key":"e_1_3_3_60_1","first-page":"838","volume-title":"Integrative Medicine","author":"Abel R","year":"2012","unstructured":"Abel R Jr . Age-related macular degeneration . In : Integrative Medicine . RakelD ( Ed. ). Elsevier Saunders , PA, USA , 838 \u2013 846 ( 2012 )."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.10.1417"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.4997"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.008"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.01.036"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.039"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.049"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.10.012"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S84155"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308624"},{"key":"e_1_3_3_70_1","unstructured":"ArcticDx . http:\/\/arcticdx.com ."},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.01.053"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S32801"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"issue":"1","key":"e_1_3_3_74_1","first-page":"143","article-title":"A potentially life-threatening adverse reaction to verteporfin","volume":"119","author":"Noffke AS","year":"2001","unstructured":"Noffke AS , JampolLM , WeinbergDV , Mu\u00f1anaA . A potentially life-threatening adverse reaction to verteporfin . Arch. Ophthalmol.119 ( 1 ), 143 ( 2001 ).","journal-title":"Arch. Ophthalmol."},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2010.167"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44020"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.09.008"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f12a4e"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700612"},{"key":"e_1_3_3_80_1","first-page":"2263","article-title":"Sequence variants in HTRA1 and LOC387715\/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel","volume":"14","author":"Chowers I","year":"2008","unstructured":"Chowers I , MeirT , LedermanMet al. Sequence variants in HTRA1 and LOC387715\/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel . Mol. Vis.14 , 2263 \u2013 2271 ( 2008 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_81_1","first-page":"1829","article-title":"Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel","volume":"14","author":"Chowers I","year":"2008","unstructured":"Chowers I , CohenY , Goldenberg-CohenNet al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel . Mol. Vis.14 , 1829 \u2013 1834 ( 2008 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702830"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1654"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.28"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.011"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.150995"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12177-010-9055-1"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.06.037"},{"issue":"13","key":"e_1_3_3_89_1","first-page":"1282","article-title":"Pharmacogenetics of complement factor H (Y402H), ARMS2 (LOC387715) and HTRA1; treatment response of exudative age-related macular degeneration with bevacizumab in Korean population","volume":"51","author":"Kang H","year":"2010","unstructured":"Kang H , KangS , ChinH . Pharmacogenetics of complement factor H (Y402H), ARMS2 (LOC387715) and HTRA1; treatment response of exudative age-related macular degeneration with bevacizumab in Korean population . Invest. Ophthalmol. Vis. Sci.51 ( 13 ), 1282 ( 2010 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181e587e3"},{"key":"e_1_3_3_91_1","first-page":"2598","article-title":"Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration","volume":"16","author":"Teper SJ","year":"2010","unstructured":"Teper SJ , NowinskaA , PilatJ , PaluchaA , WylegalaE . Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration . Mol. Vis.16 , 2598 \u2013 2604 ( 2010 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_92_1","first-page":"115","article-title":"The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis genotype study (an American Ophthalmological Society Thesis)","volume":"109","author":"Francis PJ","year":"2011","unstructured":"Francis PJ . The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis genotype study (an American Ophthalmological Society Thesis) . Trans. Am. Ophthalmol. Soc.109 , 115 \u2013 156 ( 2011 ).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"issue":"14","key":"e_1_3_3_93_1","first-page":"5259","article-title":"A pilot study of pharmacogenetics as a predictor of outcome in patients receiving intravitreal anti-VEGF therapy in age related macular degeneration (AMD)","volume":"52","author":"Kitchens JW","year":"2011","unstructured":"Kitchens JW , KassemN , WoodWet al. A pilot study of pharmacogenetics as a predictor of outcome in patients receiving intravitreal anti-VEGF therapy in age related macular degeneration (AMD) . Invest. Ophthalmol. Vis. Sci.52 ( 14 ), 5259 ( 2011 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6080"},{"issue":"14","key":"e_1_3_3_95_1","first-page":"5231","article-title":"The role of genetics and smoking in response to anti-VEGF therapy for wet AMD","volume":"52","author":"Kovach JL","year":"2011","unstructured":"Kovach JL , AgarwalA , CadeWet al. The role of genetics and smoking in response to anti-VEGF therapy for wet AMD . Invest. Opthalmol. Vis. Sci.52 ( 14 ), 5231 ( 2011 ).","journal-title":"Invest. Opthalmol. Vis. Sci."},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-011-0061-z"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.011"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.02080.x"},{"issue":"14","key":"e_1_3_3_99_1","article-title":"Polymorphic variations affecting response to anti-VEGF therapy in patients with exudative age-related macular degeneration","volume":"52","author":"Wang VM","year":"2011","unstructured":"Wang VM , RosenRB , MeyerleCBet al. Polymorphic variations affecting response to anti-VEGF therapy in patients with exudative age-related macular degeneration . Invest. Ophthalmol. Vis. Sci.52 ( 14 ), ( 2011 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6550"},{"issue":"14","key":"e_1_3_3_101_1","first-page":"2931","article-title":"Gene variants in the HTRA1 and ARMS2 genes and outcome of anti-VEGF treatment in neovascular AMD","volume":"53","author":"Abedi F","year":"2012","unstructured":"Abedi F , WickremasingheS , RichardsonAJ , IslamFMA , GuymerR , BairdPN . Gene variants in the HTRA1 and ARMS2 genes and outcome of anti-VEGF treatment in neovascular AMD . Invest. Ophthalmol. Vis. Sci.53 ( 14 ), 2931 ( 2012 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.001"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2012.26.6.414"},{"issue":"14","key":"e_1_3_3_104_1","first-page":"5168","article-title":"Long-term studies on the anti-VEGF treatment success in age-related macular degeneration (AMD)","volume":"53","author":"Kloeckener-Gruissem B","year":"2012","unstructured":"Kloeckener-Gruissem B , MenghiniM , SutterFet al. Long-term studies on the anti-VEGF treatment success in age-related macular degeneration (AMD) . Invest. Ophthalmol. Vis. Sci.53 ( 14 ), 5168 ( 2012 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.193680"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042014"},{"issue":"14","key":"e_1_3_3_107_1","first-page":"3328","article-title":"The pharmacogenetic association between genetic factors and early response to ranibizumab for exudative age-related macular degeneration","volume":"53","author":"Noh DH","year":"2012","unstructured":"Noh DH , ChangW , SagongM . The pharmacogenetic association between genetic factors and early response to ranibizumab for exudative age-related macular degeneration . Invest. Ophthalmol. Vis. Sci.53 ( 14 ), 3328 ( 2012 ).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822a2c7c"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318225290f"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.05.040"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.53"},{"key":"e_1_3_3_112_1","first-page":"2578","article-title":"Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration","volume":"18","author":"Wang VM","year":"2012","unstructured":"Wang VM , RosenRB , MeyerleCBet al. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration . Mol. Vis.18 , 2578 \u2013 2585 ( 2012 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.01.010"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.014"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.006"},{"key":"e_1_3_3_116_1","first-page":"702","article-title":"Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population","volume":"19","author":"Chang W","year":"2013","unstructured":"Chang W , NohDH , SagongM , KimIT . Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population . Mol. Vis.19 , 702 \u2013 709 ( 2013 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_117_1","first-page":"2571","article-title":"The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab","volume":"19","author":"Dikmetas O","year":"2013","unstructured":"Dikmetas O , KadayifcilarS , EldemB . The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab . Mol. Vis.19 , 2571 \u2013 2578 ( 2013 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/676049"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.11.037"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318285cf92"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S39635"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.43"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.046"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355068"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.2174\/15665240113139990048"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2585-7"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354328"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1590\/0100-69912014006002"},{"issue":"15","key":"e_1_3_3_129_1","first-page":"1","article-title":"Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population","volume":"2","author":"Habibi I","year":"2014","unstructured":"Habibi I , SfarI , ChebilAet al. Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population . Biomark. Res.2 ( 15 ), 1 \u2013 8 ( 2014 ).","journal-title":"Biomark. Res."},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.02.025"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.109"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.035"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.047"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.51"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182979e1e"},{"key":"e_1_3_3_136_1","first-page":"1680","article-title":"Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients","volume":"20","author":"Park UC","year":"2014","unstructured":"Park UC , ShinJY , McCarthyLCet al. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients . Mol. Vis.20 , 1680 \u2013 1694 ( 2014 ).","journal-title":"Mol. Vis."},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2014.949010"},{"issue":"39","key":"e_1_3_3_138_1","first-page":"1","article-title":"Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: \u2018real life\u2019 long-term outcome","volume":"15","author":"Beykin G","year":"2015","unstructured":"Beykin G , GruninM , AverbukhE , BaninE , HemoY , ChowersI . Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: \u2018real life\u2019 long-term outcome . BMC Ophthalmol.15 ( 39 ), 1 \u2013 8 ( 2015 ).","journal-title":"BMC Ophthalmol."},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.04.024"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1159\/000439172"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160819796"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12587"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1067325"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.4238\/gmr15049164"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1159\/000446819"},{"issue":"9","key":"e_1_3_3_146_1","first-page":"1304","article-title":"Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population","volume":"9","author":"Cruz-Gonzalez F","year":"2016","unstructured":"Cruz-Gonzalez F , Cabrillo-EstevezL , Rivero-GutierrezV , Sanchez-JaraA , De Juan-MarcosL , Gonzales-SarmientoR . Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population . Int. J. Ophthalmol.9 ( 9 ), 1304 \u2013 1309 ( 2016 ).","journal-title":"Int. J. Ophthalmol."},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-111801"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1159\/000446186"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.153"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000180"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep37924"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.11.033"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2016.01.006"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001554"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475995"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1311925"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3748-0"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09632-0"},{"key":"e_1_3_3_159_1","unstructured":"Institute for Prospective Technological Studies . Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impact in the EU . European Communities Luxembourg ( 2006 )."},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2578"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3448"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110359"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2001.1800103.x"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.1086\/431426"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0776-3"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.02.003"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-09-0473"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1133811"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.1247\/csf.26.25"},{"key":"e_1_3_3_171_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000134"},{"key":"e_1_3_3_172_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0483-1"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2012.03.006"},{"key":"e_1_3_3_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.03.013"},{"key":"e_1_3_3_175_1","volume-title":"Regression Modeling Strategies With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis (2nd Edition)","author":"Harrell FE","year":"2015","unstructured":"Harrell FE Jr . Regression Modeling Strategies With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis (2nd Edition) . Springer , NY, USA ( 2015 )."},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.70"},{"key":"e_1_3_3_177_1","doi-asserted-by":"publisher","DOI":"10.1590\/2176-9451.19.4.027-029.ebo"},{"key":"e_1_3_3_178_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2014.888569"},{"key":"e_1_3_3_179_1","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (an AOS thesis)","volume":"107","author":"Kaiser PK","year":"2009","unstructured":"Kaiser PK . Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (an AOS thesis) . Trans. Am. Ophthalmol. Soc.107 , 311 \u2013 324 ( 2009 ).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"e_1_3_3_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.06.047"},{"key":"e_1_3_3_181_1","first-page":"300","volume-title":"Retina (5th Edition)","author":"Rubin GS","year":"2013","unstructured":"Rubin GS . Chapter 11 \u2013 Visual acuity and contrast sensitivity . In : Retina (5th Edition) . StephenJ. Ryan ( Ed. ). Elsevier Saunders , PA, USA , 300 \u2013 306 ( 2013 )."},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18255-4"},{"key":"e_1_3_3_183_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.48"},{"key":"e_1_3_3_184_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0391-4"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.159160"},{"key":"e_1_3_3_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.019"},{"key":"e_1_3_3_187_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304775"},{"key":"e_1_3_3_188_1","first-page":"56","article-title":"Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society Thesis)","volume":"111","author":"Stein JD","year":"2013","unstructured":"Stein JD , Newman-CaseyPA , MrinaliniT , LeePP , HuttonDW . Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society Thesis) . Trans. Am. Ophthalmol. Soc.111 , 56 \u2013 69 ( 2013 ).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"e_1_3_3_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.037"},{"key":"e_1_3_3_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.01.003"},{"key":"e_1_3_3_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.10.021"},{"key":"e_1_3_3_192_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13031"},{"key":"e_1_3_3_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.009"},{"key":"e_1_3_3_194_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.02.009"},{"key":"e_1_3_3_195_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2012.04.004"},{"key":"e_1_3_3_196_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.306"},{"key":"e_1_3_3_197_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12103"},{"key":"e_1_3_3_198_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160030"},{"key":"e_1_3_3_199_1","unstructured":"PubMed . https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/ ."},{"key":"e_1_3_3_200_1","unstructured":"Google Scholar . https:\/\/scholar.google.com.au\/ ."},{"key":"e_1_3_3_201_1","unstructured":"Clinical Pharmacogenetics Implementation Consortium . https:\/\/cpicpgx.org\/ ."}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs-2017-0183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:32:24Z","timestamp":1715999544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs-2017-0183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":200,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.2217\/pgs-2017-0183"],"URL":"https:\/\/doi.org\/10.2217\/pgs-2017-0183","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}